Most Favored Patient Act: Lowering Drug Prices to International Levels
This act aims to lower prescription drug costs for Medicare and Medicaid patients by linking US prices to lower prices paid in other developed nations. It encourages drug companies to manufacture more products within the United States to avoid these price caps.
Key points
Drug prices for Medicare and Medicaid will be based on the second-lowest price found in countries like Canada, France, and Japan.
The model applies to drugs dispensed at pharmacies and those administered in hospitals or doctors' offices.
Manufacturers can opt-out of the pricing model if they agree to increase their manufacturing operations in the U.S.
The new pricing system is scheduled to begin on January 1, 2029, for a five-year period.
Status:
Introduced
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.